Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Up 5.69%
As of Wednesday, October 14, Electra Therapeutics, Inc.’s ETRA share price has surged by 5.69%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Commentary & Analysis
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 5.46%
As of Thursday, October 08, Electra Therapeutics, Inc.’s ETRA share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 6.31%
As of Wednesday, October 07, Electra Therapeutics, Inc.’s ETRA share price has dipped by 6.31%, which has investors questioning if this is right time to buy.Michael Rose
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 8.77%
As of Monday, October 05, Electra Therapeutics, Inc.’s ETRA share price has dipped by 8.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $540.4 | $224.8 | 39% |
|
| Shares Out (Mil) | 0.0 | 53.9 | 0% |
|
| Institutional Ownership | na | 93.1% | na |
|
| Float (Mil) | na | 40.6 | na |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 598 | 632 | 61% |
|
| Price Change (52-week) |
na | 47.3% | na |
|
| Growth | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | na | (10.2%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($44) | 12% |
|
| EPS (TTM) | na | ($1.600) | na |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $50 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $1,047 | $174 | 41% |
|
| Valuation | ETRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (160.6%) | (47.7%) | 3% |
|
| ROE | 77.9% | (55.0%) | 95% |
|
| Liabilities to Assets | 13.9% | 29.4% | 9% |
|
| F-Score | 1 | 3 | na |
|
Electra Therapeutics, Inc. did not pass any screens on 10/13/2026.
